论文部分内容阅读
目的观察雷贝拉唑、莫沙必利和铝镁加联合治疗反流性食管炎(RE)的临床疗效。方法 118例RE患者,按照治疗方案的不同分为对照组(53例)和研究组(65例)。对照组采用雷贝拉唑、莫沙必利治疗,研究组在对照组基础上联合铝镁加治疗,对比两组治疗效果及不良反应情况。结果研究组胃灼热、呕吐、反酸、胸骨疼痛、胃胀评分分别为(1.03±1.14)、(1.01±0.52)、(1.12±0.34)、(0.77±0.64)、(1.11±0.20)分,低于对照组的(2.89±1.45)、(1.89±0.59)、(2.68±1.26)、(1.75±0.42)、(1.89±0.40)分,差异具有统计学意义(P<0.05)。研究组发生腹泻3例(4.62%)、头晕4例(6.15%),对照组分别为4例(7.55%)、4例(7.55%),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论反流性食管炎行雷贝拉唑、莫沙必利联合铝镁加治疗可取得显著效果,且安全性高,值得应用。
Objective To observe the clinical efficacy of rabeprazole, mosapride and aluminum-magnesium plus combined therapy for reflux esophagitis (RE). Methods 118 patients with RE were divided into control group (n = 53) and study group (n = 65) according to the different treatment plans. The rabbits in the control group were treated with rabeprazole and mosapride, the study group was treated with aluminum magnesium plus magnesium on the basis of the control group, and the treatment effect and adverse reactions were compared between the two groups. Results The scores of heartburn, vomiting, acid reflux, sternal pain and bloating in the study group were (1.03 ± 1.14), (1.01 ± 0.52), (1.12 ± 0.34), (0.77 ± 0.64) and (1.11 ± 0.20) (2.89 ± 1.45), (1.89 ± 0.59), (2.68 ± 1.26), (1.75 ± 0.42) and (1.89 ± 0.40) respectively in the control group. The difference was statistically significant (P <0.05). There were 3 cases (4.62%) with diarrhea and 4 cases (6.15%) with dizziness in the study group, 4 cases (7.55%) and 4 cases (7.55%) in the control group respectively. There was no significant difference in the incidence of adverse reactions between the two groups P> 0.05). Conclusion Reflux esophagitis, rabeprazole, mosapride and aluminum magnesium plus treatment can achieve significant results, and high safety, it is worth to apply.